3-(Acetylamino)-4-(2-methylpiperidin-1-yl)benzoic acid → Methyl 4-{5-[3-(acetylamino)-4-(2-methylpiperidin-1-yl)phenyl]-1,2,4-oxadiazol-3-yl}-2-fluorobenzoate

Beteiligte Stoffe

Reaktionsschritte

The title compound was obtained following procedure described for example 4, step 1, but starting from Intermediate 1 (70 mg; 0.33 mmol) and Intermediate 32 (91.17 mg; 0.33 mmol). Title compound was isolated after trituration with MeOH as an off-white powder. 1H NMR (DMSO-d6, 300 MHz) δ 9.10 (bs, 1H), 8.88, (bs, 1H), 8.11 (t, J=7.6 Hz, 1H), 8.03 (dd, J=8.1, 1.5 Hz, 1H), 7.97-7.87 (m, 2H), 7.45 (d, 8.4 Hz, 1H), 3.90 (s, 3H), 3.19-3.12 (m, 1H), 2.96-2.89 (m, 1H), 2.65-2.57 (m, 1H), 2.19 (s, 3H), 1.87-1.66 (m, 4H), 1.53-1.44 (m, 2H), 0.84 (d, J=6 Hz, 3H). LC/MS (Method B): 453.3 (M+H)+. HPLC (Method A) Rt 5.16 min (purity: 97.5%).

Herkunft & Nachweise